Amylyx Pharmaceuticals, Inc. (AMLX) Stock Price & How to Invest

Amylyx Pharmaceuticals develops treatments for neurodegenerative and endocrine conditions with few or no approved options. Its lead program is avexitide, a GLP-1 antagonist being tested in adults with post-bariatric hypoglycemia (PBH), a condition where people who have had Roux-en-Y gastric bypass surgery experience severe blood-sugar crashes. The pivotal Phase 3 LUCIDITY trial enrolled 78 participants across a 16-week blinded period, completed its final participant visit in mid-2026, and reads out topline in late August or early September 2026. Behind it sit AMX0035 in Wolfram syndrome (a focused pivotal Phase 3 was guided for the second half of 2026 after extended Phase 2 HELIOS data showed trends in pancreatic function and vision stabilization), AMX0114 in ALS (Phase 1 LUMINA data reported as safety-supportive), and AMX0318 in IND-enabling studies.

The investment picture is unusually concentrated. Amylyx has no meaningful product revenue today: its first approved drug, Relyvrio for ALS, was pulled from the market in 2024 after the confirmatory PHOENIX Phase 3 trial missed, which reset the company from commercial-stage back to clinical-stage and left a lasting credibility question that management has been rebuilding against ever since. What it does have is a funded balance sheet, roughly $250.8 million in cash, cash equivalents and short-term investments as of June 30, 2026, with runway guided into 2028, which covers a potential avexitide approval and a 2027 launch without a forced financing. Against a market capitalization near $2 billion, most of that value is the market's probability-weighted view of one dataset, so the shares tend to trade on trial timelines and regulatory language rather than on quarterly financials.

The concentration risk is the dominant one: a single Phase 3 readout in a small 78-patient trial decides most of the equity value, and small trials are more vulnerable to placebo response and endpoint variability than large ones. Amylyx has already failed a confirmatory Phase 3 once, with Relyvrio withdrawn from the market in 2024, so execution credibility is not assumed by the market. Even a positive dataset leaves FDA review risk, label risk, and the operational cost of building a commercial organization for a rare condition. The company generates no product revenue and burns roughly $40 million a quarter, so any delay pushes it toward a financing that would dilute existing holders. There is also a legacy legal item: a securities class action tied to 2022 to 2023 Relyvrio launch statements was settled for $6.5 million, with preliminary court approval in May 2026 and a final approval hearing scheduled for September 2026.

9 analysts publish price targets on AMLX, averaging $27.44 against a $22.82 price as of August 2026, or +20.2%. The published targets run from $21.00 to $40.00, a moderate spread, and the ratings split 10 buy, 1 hold, 0 sell. Over the last six months there have been 8 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AMLX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Amylyx Pharmaceuticals, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. The LUCIDITY Phase 3 readout. Topline data from the 78-participant pivotal trial of avexitide in post-bariatric hypoglycemia are expected in late August or early September 2026. The most optimistic published target, $40.00, assumes this works close to its best case.

The case against. The concentration risk is the dominant one: a single Phase 3 readout in a small 78-patient trial decides most of the equity value, and small trials are more vulnerable to placebo response and endpoint variability than large ones. The most pessimistic target, $21.00, is roughly what AMLX is worth if this bites instead.

Read the full bull and bear case on AMLX, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Amylyx Pharmaceuticals, Inc.'s investor relations page or your broker.

• Product revenue: None (Relyvrio withdrawn in 2024)
• Cash and equivalents: ~$250.8M (June 30, 2026)
• Cash runway: Guided into 2028
• R&D expense (H1 2026): ~$51.4M
• Net loss (H1 2026): ~$84.7M, or ~$0.76 per share
• Market cap: ~$2.0B

Standard valuation multiples do not apply here because there is no revenue and no path to profitability without an approval. The market is pricing a probability of avexitide reaching the market against a fully funded cost base, which is why the roughly $2 billion capitalization sits on top of about $250 million of cash and an annualized loss near $170 million. Watch the cash line and the runway guidance each quarter, because that is what determines whether Amylyx negotiates a post-readout financing from strength or from need.

Other names that sit close to AMLX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AMLX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AMLX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AMLX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Amylyx is a funded, single-catalyst biotech where one readout in the next few weeks decides most of the story.

Whether AMLX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AMLX a buy or a sell?, and where the stock could go from here in the AMLX stock forecast.

For income investors, whether AMLX pays a dividend and how the payout looks is covered in does AMLX pay a dividend? And to weigh AMLX against a peer, read the full side-by-side comparisons: AMLX vs CRNX and AMLX vs CNS.